Bio-Techne misses revenue estimates as US academic funding cuts dent demand
Published on 05/06/2026 at 07:30 am EDT
Reuters
Share
Share
|
Market Closed -
Other stock markets
|
After hours 08:00:00 pm | |||
| 54.02 USD | +2.90% |
|
53.03 | -1.83% |
![Kim Kelderman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kim Kelderman is currently President, Chief Executive Officer & Director at Bio-Techne Corp.
since 2024, Chief Executive Officer at Bio-Techne Sales Corp., Director at SLMP LLC since 2021, Independent Director at CONMED Corp.
starting 2025, General Manager at GeneOhm Sciences Canada ULC, and President at Bionostics, Inc. Former roles include Principal at EndoSonics Corp., Chief Operating Officer at Sonoma Pharmaceuticals, Inc., Principal at Jomed Imaging Ltd., Principal at Medtronic CardioVascular, and President & General Manager at Jomed, Inc. Education includes undergraduate studies at Zuyd University of Applied Sciences.
Employees
3,100
Trader
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
AA
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
54.02USD
Average target price
61.69USD
Spread / Average Target
+14.20%
Quarterly revenue - Rate of surprise
- Stock Market
- Stock Market News
- Bio-Techne misses revenue estimates as US academic funding cuts dent demand
Select your edition
All financial news and data tailored to specific country editions
